Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Nashington,	D.C. 20549
-------------	------------

STATEMENT	OF	CHANGES	IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response	e: 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) (First) (Middle) C/O SAGE THERAPEUTICS, INC. 215 FIRST STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) Date (Month/Day/Year) A 10,000(1) A \$0.00 131,981 D	1. Name and Address of Reporting Person* JONAS JEFFREY M					Sag	Issuer Name and Ticker or Trading Symbol Sage Therapeutics, Inc. [SAGE] Date of Earliest Transaction (Month/Day/Year)								ck all app Direc	,	ng Per	rson(s) to Is 10% Over (s)	wner	
215 FIRST STREET (Street) CAMBRIDGE MA 02142 Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction or written plan that is intended to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction of Rule 10b5-1	(Last)	(Fi	rst) (I	Middle)															opcony	
City Cambridge	l					4. If A								Line)	ne)					
Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Price of Date (Instr. 4) Common Stock 11/28/2023 Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 3, 4 and 5) Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 3) Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 3) Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 4) Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 4) Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 4) Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 4) Table II - Derivative Securities Acquired, Disposed Of (D) (Instr. 4) Table II - Derivative Securities Acquired, Disposed Of Or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities Security (Instr. 4) Table II - Derivative Securities Acquired (D) or Date (D) or Indirect (D	l` ′	IDGE M	A 0)2142											_ ^	Form	filed by Mo		•	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Date (Month/Day/Year) 2. Transaction Date (Instr. 4) 2. Transaction Date (Instr. 4) 2. Transaction Date (Instr. 3) 2. Transaction Date (Month/Day/Year) Date (Month/Day/Year) 2. Transaction Date (Instr. 3) 3. Transaction (Instr. 3) 3. Transaction Date (Instr. 3) 3. Transaction (Instr. 4)	,———	IDGE W				Rul	e 10)b5-	1(c)	Tran	sac	tion Indi	icatio	on						
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Deemed Execution Date if any (Month/Day/Year) 2. Deemed Execution Date if any (Month/Day/Year) 2. Deemed Execution Date if any (Month/Day/Year) 3. Transaction Code (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 4) 6. Ownership Form: Direct (D) or Indirect Clored Ind	(City)	(St	ate) (2	Zip)			Check the atisfy the	nis box ne affiri	to indi mative	cate that defense	a tran	saction was mons of Rule 10	ade pui 0b5-1(c	suant t	o a cor	tract, instru on 10.	uction or writt	en plai	n that is inte	nded to
Date (Month/Day/Year) Month/Day/Year) Mont			Table	I - No	n-Deriva	tive S	Secui	rities	Acc	uired	, Dis	posed of	, or E	Bene	ficial	ly Own	ed			
Common Stock 11/28/2023 A 10,000(1) A \$0.00 131,981 D Common Stock 11/28/2023 F 3,935 D \$19.27 128,046 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Securities (Month/Day/Year) 2. Conversion of Exercise Price of Derivative Securities (A) or Disposed of (D) (Instr. 3) (Instr. 4) 3. Transaction Date Exercisable and Expiration Date (Month/Day/Year) 5. Number of Derivative Securities Securities Underlying Derivative Securities Securities Underlying Reported Transaction(s) (Instr. 4) 6. Date Exercisable and Expiration Date (Month/Day/Year) Securities Securities Securities Underlying Reported Transaction(s) (Instr. 4) 7. Title and Amount of Securities Securities Securities Securities Securities Underlying Reported Transaction(s) (Instr. 4) 8. Price of Derivative Securities Sec	Date			Execution Date, if any		Transaction Disposed O Code (Instr. 5)				4 and Secur Bene Owne		rities Fricially (I d Following (I		Form: Direct D) or Indirect I) (Instr. 4)	of Indirect Beneficial Ownership					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 1. Title of Derivative Security 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) Amount or Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Amount or Amount or Security (Instr. 3) Amount or Amount or Security (Instr. 4) Amount or Security (Instr. 4)										Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s)			(moti. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 2. Conversion of Exercise (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3) and 4) 8. Price of Derivative Security (Instr. 5) 8. Price of Derivative Securities (Month/Day/Year) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(Instr. 4) 10. Ownership Form: One Disposed of (D) (Instr. 3, 4 and 5) 11. Nature (Month/Day/Year) 12. Amount of Amount of Securities Underlying Derivative Security (Instr. 3) 13. Transaction Date (Inderlying Derivative Security (Instr. 4) 14. Amount of Amount of Securities Underlying Derivative Securities (Instr. 4) 15. Number of Derivative Securities (Inderlying Derivative Security (Instr. 4) 16. Date Exercisable and Expiration Date (Month/Day/Year) 17. Title and Amount of Securities Underlying Derivative Securities (Inderlying Derivative Security (Instr. 4) 16. Date Exercisable and Expiration Date (Month/Day/Year) 17. Title and Amount of Securities Underlying Derivative Securities (Inderlying Derivative Securities Underlying Derivative Securities Unde	Common	Stock			11/28/2	.023			A		10,000(1)	A \$0.00		00 131,981			D			
(e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) Instr. 3) (Instr. 4)	Common Stock 11/28/			11/28/2	023 F 3,935 D			9	19.27	9.27 128,046 D										
Derivative Security (Instr. 3) Price of Derivative Security Securities Security Security Securities Securities Security Securities Secur																				
	Derivative Security	Conversion or Exercise Price of Derivative	Date	Execut if any	tion Date,	Transa Code (Fransaction Code (Instr. B) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		vative rities rired r osed)	Expiration Date		Amount of Securities Underlying Derivative Security (Ins. 3 and 4)		str.	erivative ecurity	derivative Securities Beneficiall Owned Following Reported Transactio	y	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

1. On March 25, 2020, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 25,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on November 28, 2023, resulting in the vesting of the PSUs as to 10,000 shares.

Remarks:

/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey

11/30/2023

M. Jonas

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

- I, the undersigned, hereby authorize and designate Anne Marie Cook (SVP, General Counsel), Kimi Iguchi (Chief Financial Officer), Erin Lanciani (SVP, People and Organizational Strategy), and Jennifer Fitzpatrick (Vice President, Corporate Counsel) for as long as they remain employees of Sage Therapeutics, Inc., and Laurie Burlingame of Goodwin Procter, each acting singly, or their successors in role, to take the following actions, acting as my agent and attorney-in-fact, with full power of substitution:
- (1) to prepare and sign on my behalf any Form 3, Form 4 or Form 5 pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, and to file the same with the Securities and Exchange Commission, NASDAQ, NYSE, and each stock exchange on which shares of Common Stock or other securities of Sage Therapeutics, Inc. are listed, as required by law;
- (2) to prepare and sign on my behalf any Form 144 pursuant to the Securities Act of 1933, as amended, and to file the same with the Securities and Exchange Commission, NASDAQ, NYSE, and each stock exchange on which shares of Common Stock or other securities of Sage Therapeutics, Inc. are listed, as required by law; and
- $% \left(1\right) =\left(1\right) ^{2}$ (3) take any other action necessary or proper in connection with the foregoing.

Unless earlier revoked under the next sentence, this Power of Attorney shall remain in effect as long as I am an executive officer or director of Sage Therapeutics, Inc., and shall not be affected by my subsequent disability or incompetence. I may revoke this Power of Attorney by written notice delivered, in person or by nationally recognized courier, to the attention of the SVP, General Counsel of Sage Therapeutics, Inc.

/s/ Jeff Jonas

(Signature of Executive Officer or Director)

Name: Jeff JOnas

Date: 12/13/2018